Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069732 | 0.81 | NAALAD2 (0.51) | NAALAD2TSHRGLACYP1A2GHSR | |
| SCHEMBL10240204 | 0.81 | ALDH1A1 (0.33) | NAALAD2KMT2ALMNACYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15253870 | 0.80 | NAALAD2 (0.45) | NAALAD2TSHRGLAKMT2ALMNA | |
| SCHEMBL7344053 | 0.79 | NAALAD2 (0.52) | NAALAD2TSHRGLACYP1A2GHSR | |
| SCHEMBL4403621 | 0.78 | ALDH1A1 (0.44) | KMT2ALMNACYP1A2ALDH1A1 | |
| SCHEMBL15254266 | 0.75 | NAALAD2 (0.49) | NAALAD2TSHRGLAKMT2ALMNA | |
| SCHEMBL13252477 | 0.75 | KMT2A (0.36) | KMT2ALMNACYP1A2ALDH1A1GAA | |
| SCHEMBL96932 | 0.75 | KMT2A (0.43) | TSHRKMT2ALMNAALDH1A1GAA | |
| SCHEMBL2056129 | 0.73 | — | — | |
| SCHEMBL10673194 | 0.73 | GLA (0.42) | NAALAD2TSHRGLAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | NAALAD2 1380/4885TSHR 501/4885GLA 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.